Publications by authors named "G Toyokawa"
Impact of the distance of spread through air spaces in non-small cell lung cancer.
Interdiscip Cardiovasc Thorac Surg
December 2024
Objectives: Spread through air spaces (STAS) is considered a poor prognostic factor in patients with resected non-small lung cell cancer; however, the clinical significance of STAS extent remains unclear. We hypothesized that the further the tumour cells spread from the tumour edge, the worse the prognosis becomes.
Methods: This study retrospectively reviewed the data of 642 patients with completely resected pathological stage I-III non-small lung cell cancer between 2008 and 2018.
Article Synopsis
- - Bronchiolitis obliterans syndrome (BOS) is a serious complication after lung transplants that affects long-term survival, and this study explores the role of EZH2 in BOS.
- - The research involved administering a drug called 3-deazaneplanocin A (DZNep) to mice with transplanted tracheas, showing that DZNep significantly reduced obstruction ratios and levels of various inflammatory cytokines at different time points.
- - Results indicated that DZNep treatment decreased T-cell infiltration and inflammatory responses, suggesting its potential as a therapy to mitigate BOS symptoms post-lung transplantation.
Introduction: Platinum-based chemotherapy is the mainstay of first-line therapy for advanced-stage non-small cell lung cancer (NSCLC). Although carboplatin-induced hypersensitivity reactions (HSRs) commonly occur following multiple cycles of therapy, they are rarely observed during the first cycle of the treatment.
Case Report: Here, we report the case of a 70-year-old man with advanced-stage NSCLC who developed HSR possibly caused by carboplatin during the first cycle of induction with platinum-doublet chemotherapy plus pembrolizumab.
Article Synopsis
- * A study identified that hypoxanthine phosphoribosyltransferase 1 (HPRT1) helps SCLC cells survive in low-glutamine environments, indicating its role in cancer progression.
- * Combining HPRT1 inhibition with other drugs targeting purine synthesis pathways showed significant tumor suppression in mouse models, suggesting a promising new therapeutic strategy for SCLC.
Background: Immunotherapy has become a standard-of-care for patients with non-small-cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death-1, have been shown to be useful in selecting patients likely to benefit from immune checkpoint inhibitors (ICIs), more useful and reliable ones should be investigated. The prognostic nutritional index (PNI) is a marker of the immune and nutritional status of the host, and is derived from serum albumin level and peripheral lymphocyte count.
View Article and Find Full Text PDF